Biotech News

Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion Therapeutics (ESPR)Esperion Therapeutics2026-10-07 12:00 ESTCompany update

ANN ARBOR, Mich., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Renata in

Related news

ESPREsperion Therapeutics2026-03-30 12:00 EST

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

ESPREsperion Therapeutics2026-03-16 10:30 EST

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

View all latest news

Esperion Therapeutics

Oral Cardiometabolic Medicines Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase. Bempedoic Acid Franchise NEXLETOL and NEXLIZET are once-daily, non-statin...

Recent company news

ESPREsperion Therapeutics2026-10-07 12:00 EST

Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

ESPREsperion Therapeutics2026-09-30 12:00 EST

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

ESPREsperion Therapeutics2026-05-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-05-14 20:30 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPREsperion Therapeutics2026-05-13 12:00 EST

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Stock data

Close: 3.18 USD
Market cap: 808.34M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States